BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...the spike protein. Other companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor Therapeutics Inc....
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...ARDS, the evasins could stop cytokine storms. Capricor gains on COVID-19 cell therapy compassionate use Capricor Therapeutics Inc....
...TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor Therapeutics Inc. Interferon...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...and Clover Biopharmaceuticals (see “GSK to Provide Adjuvant” ). Capricor, Revive redirect candidates to COVID-19 Capricor Therapeutics Inc....
...plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology Innovation Organization XBiotech Inc. U.S. Department of Defense Eurofins Scientific S.E. Becton Dickinson and Co. Capricor Therapeutics Inc. cov19count COVID-19 cov19count...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...from PRIMA at an upcoming scientific meeting. Capricor climbs on interim Phase II DMD data Capricor Therapeutics Inc....
...Mary Romeo, Assistant Editor Ad26.Mos4.HIV AVR-RD-01, avr-02 CAP-1002 Zejula (Brand), ZL-2306 (Compound #), MK-4827 (Compound #), niraparib (Generic), Zejula (Informal) Avrobio Capricor Therapeutics Inc. GlaxoSmithKline...
BioCentury | Feb 8, 2019
Clinical News

Capricor resumes DMD trial, will seek funding

...Sept. 30, 2018, Capricor had $4.4 million in cash. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc....
...wall thickening at months six and 12, and safety Status: Phase II resumed Milestone: NA Chris Lieu CAP-1002 Capricor Therapeutics Inc. Muscular...
BioCentury | Jan 4, 2019
Clinical News

Capricor places DMD trial on hold

...of Performance of the Upper Limb at month 12. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc....
...thickening at months six and 12, and safety Status: Phase II clinical hold Milestone: NA Meghan Sullivan CAP-1002 Capricor Therapeutics Inc....
BioCentury | Jan 19, 2018
Company News

Capricor and Cedars-Sinai expand cardiosphere deal

...Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights to develop...
...heart syndrome. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Cedars-Sinai Medical Center, Los Angeles, Calif. Business: Cardiovascular Allison Johnson CAP-1002 CAP-2003 Capricor Therapeutics Inc. Cedars-Sinai...
BioCentury | Nov 9, 2017
Targets & Mechanisms

Vesicular fuel

...included in the figure are as follows (clockwise from lower right): Exovita Biosciences Inc. , Capricor Therapeutics Inc....
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...use data from the trial, expected in 2H19, to support an NDA submission. Jaime De Leon AVI-4658 CAP-1002 deflazacort Emflaza eteplirsen Exondys 51 idebenone MP-104 Raxone SNT-MC17 Capricor Therapeutics Inc. Parent...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...to CAP-1002 to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002 Business: Musculoskeletal Jaime De Leon CAP-1002 Capricor Therapeutics Inc....
Items per page:
1 - 10 of 47
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...the spike protein. Other companies that have disclosed preclinical mRNA vaccine programs for COVID-19 include Capricor Therapeutics Inc....
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...ARDS, the evasins could stop cytokine storms. Capricor gains on COVID-19 cell therapy compassionate use Capricor Therapeutics Inc....
...TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Pear Therapeutics Capricor Therapeutics Inc. Interferon...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...and Clover Biopharmaceuticals (see “GSK to Provide Adjuvant” ). Capricor, Revive redirect candidates to COVID-19 Capricor Therapeutics Inc....
...plc Emergent BioSolutions Inc. SAB Biotherapeutics Inc. Biotechnology Innovation Organization XBiotech Inc. U.S. Department of Defense Eurofins Scientific S.E. Becton Dickinson and Co. Capricor Therapeutics Inc. cov19count COVID-19 cov19count...
BioCentury | Jul 16, 2019
Clinical News

July 15 Clinical Quick Takes: Zejula meets in Phase III for 1L ovarian cancer; plus Capricor, Avrobio and NIH

...from PRIMA at an upcoming scientific meeting. Capricor climbs on interim Phase II DMD data Capricor Therapeutics Inc....
...Mary Romeo, Assistant Editor Ad26.Mos4.HIV AVR-RD-01, avr-02 CAP-1002 Zejula (Brand), ZL-2306 (Compound #), MK-4827 (Compound #), niraparib (Generic), Zejula (Informal) Avrobio Capricor Therapeutics Inc. GlaxoSmithKline...
BioCentury | Feb 8, 2019
Clinical News

Capricor resumes DMD trial, will seek funding

...Sept. 30, 2018, Capricor had $4.4 million in cash. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc....
...wall thickening at months six and 12, and safety Status: Phase II resumed Milestone: NA Chris Lieu CAP-1002 Capricor Therapeutics Inc. Muscular...
BioCentury | Jan 4, 2019
Clinical News

Capricor places DMD trial on hold

...of Performance of the Upper Limb at month 12. CAP-1002 comprises allogeneic cardiosphere-derived stem cells. Capricor Therapeutics Inc....
...thickening at months six and 12, and safety Status: Phase II clinical hold Milestone: NA Meghan Sullivan CAP-1002 Capricor Therapeutics Inc....
BioCentury | Jan 19, 2018
Company News

Capricor and Cedars-Sinai expand cardiosphere deal

...Cedars-Sinai Medical Center (Los Angeles, Calif.) granted cardiovascular company Capricor Therapeutics Inc. (NASDAQ:CAPR) exclusive, worldwide rights to develop...
...heart syndrome. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Cedars-Sinai Medical Center, Los Angeles, Calif. Business: Cardiovascular Allison Johnson CAP-1002 CAP-2003 Capricor Therapeutics Inc. Cedars-Sinai...
BioCentury | Nov 9, 2017
Targets & Mechanisms

Vesicular fuel

...included in the figure are as follows (clockwise from lower right): Exovita Biosciences Inc. , Capricor Therapeutics Inc....
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...use data from the trial, expected in 2H19, to support an NDA submission. Jaime De Leon AVI-4658 CAP-1002 deflazacort Emflaza eteplirsen Exondys 51 idebenone MP-104 Raxone SNT-MC17 Capricor Therapeutics Inc. Parent...
BioCentury | Jul 28, 2017
Clinical News

FDA to allow limb function endpoint in Capricor's DMD trials

...to CAP-1002 to treat DMD. Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Product: CAP-1002 Business: Musculoskeletal Jaime De Leon CAP-1002 Capricor Therapeutics Inc....
Items per page:
1 - 10 of 47